Lionco Pharmaceutical Group Co.,Ltd.
603669.SS
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.96B
Close$
$-2.17
130% downside
Current Fair Value
130% downsideOvervalued by 130% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.96 Billion |
|---|---|
| Enterprise Value | $5.13 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.27 |
| Beta | 0.24 |
| Outstanding Shares | 703,545,265 |
Return
| Return on Equity | -21.26% |
|---|---|
| Return on Assets | -12.13% |
| Return on Invested Capital | -17.21% |
Valuation & Multiples
| P/E Ratio | -35.1 |
|---|---|
| PEG | 17.03 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 12.56 |
| Enterprise Value to EBIT | -44.74 |
| Enterprise Value to Net Income | -38 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.52 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Lionco Pharmaceutical Group Co.,Ltd.
284 employees
CEO: Ling Ping Tao Lionco Pharmaceutical Group Co., Ltd., in collaboration with its various subsidiaries, actively participates in the entire lifecycle of pharmaceutical products within China, from initial research and development to manufacturing and sale...